about
Cdk6-dependent regulation of G(1) length controls adult neurogenesisSubstituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer ActivitiesDisruption of myocardial Gata4 and Tbx5 results in defects in cardiomyocyte proliferation and atrioventricular septation.Concurrent deletion of cyclin E1 and cyclin-dependent kinase 2 in hepatocytes inhibits DNA replication and liver regeneration in miceDistinct p21 requirements for regulating normal and self-reactive T cells through IFN-γ production.Tudor staphylococcal nuclease (Tudor-SN), a novel regulator facilitating G1/S phase transition, acting as a co-activator of E2F-1 in cell cycle regulation.Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways.Cyclin-Dependent Kinase Inhibitors as Anticancer TherapeuticsCDK4: A Key Player in the Cell Cycle, Development, and CancerAurora B prevents delayed DNA replication and premature mitotic exit by repressing p21(Cip1).AMP-activated protein kinase phosphorylates retinoblastoma protein to control mammalian brain developmentActivation of NFAT signaling establishes a tumorigenic microenvironment through cell autonomous and non-cell autonomous mechanisms.Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma.Palbociclib has antitumour effects on Pten-deficient endometrial neoplasias.CDK1 inhibition targets the p53-NOXA-MCL1 axis, selectively kills embryonic stem cells, and prevents teratoma formation.Computer-aided design, synthesis and validation of 2-phenylquinazolinone fragments as CDK9 inhibitors with anti-HIV-1 Tat-mediated transcription activity.Inhibitors of cyclin-dependent kinases as cancer therapeutics.CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol.In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83.P27Kip1 serine 10 phosphorylation determines its metabolism and interaction with cyclin-dependent kinases.Rescue of cell cycle progression in BRAFV600E inhibitor-resistant human melanoma by a chromatin modifier.Haematopoietic focal adhesion kinase deficiency alters haematopoietic homeostasis to drive tumour metastasis.Hierarchy of a regenerative cell cycle: cyclin E1 multitasks.Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.CDC-25.1 controls the rate of germline mitotic cell cycle by counteracting WEE-1.3 and by positively regulating CDK-1 in Caenorhabditis elegans.
P2860
Q24293050-80D78E8E-9959-4088-86A8-78B7DD8890EEQ27675842-3E1825C6-42B6-4888-9964-DE7E900EEDE9Q34155354-FFF0D016-B602-4017-A081-08AA0F5ECCB6Q34537913-E360CB48-7AEA-4330-8D83-63ED40390164Q34877991-97DEC12F-778A-4F8B-8834-46A86CC1C252Q35172690-1DED4223-3AB2-40C3-88C5-16F487D0B44DQ35921803-CEA6FCD5-F12A-4DD5-AE46-F748215A052DQ36186117-331C0663-D645-48E0-BEA6-6F43E864F11EQ36796424-AC88D38C-C9B9-4D46-800E-BFC10FFC4B43Q36823669-BC79CD50-899C-429F-9627-B6FCE046138EQ37143228-D6014F74-201F-4186-B592-DC450B31C11DQ37164683-877BBCE5-ABE3-4EDF-BAEE-BE7DD1DD91B5Q37833892-9D8E3FDF-1101-4306-95FA-9D1484233F7DQ38734002-C7FC0D09-18F1-44AD-A552-04B81F4B346FQ38778367-CFB78041-BDB0-424B-A605-D4663EC60BE4Q38871799-7F502959-CBB0-4B91-9AC8-05C53332D168Q38904477-94D483FB-3BA2-4EEA-B9CF-C0121AE87430Q39073158-58CC2107-57F5-44FC-9473-606CFEB1B70FQ39125016-5170227D-0EB1-4425-B63A-2319C393D9FCQ39560150-DECA93AB-9B5B-47F3-AC85-DEBC907256D5Q39589955-4C2C9B60-7F5E-4A3A-A710-412A37EA4CC2Q43207235-727556AB-82E2-46B0-ADF5-1A0E90EF71C1Q46103191-5AD34BD7-C3EA-4198-95F6-AE54E547B3BFQ47806801-06B19451-9E97-4643-A36E-14DB9FC7F3BFQ47863695-24986B97-9154-4D6B-B960-5D690DE47AE8Q50711550-CA0A634C-F7C7-4F95-83BB-61E0FB466F73Q53179587-0FE558C3-A3F0-4983-8BE6-B4453512D12F
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Mice thrive without Cdk4 and Cdk2.
@ast
Mice thrive without Cdk4 and Cdk2.
@en
Mice thrive without Cdk4 and Cdk2.
@nl
type
label
Mice thrive without Cdk4 and Cdk2.
@ast
Mice thrive without Cdk4 and Cdk2.
@en
Mice thrive without Cdk4 and Cdk2.
@nl
prefLabel
Mice thrive without Cdk4 and Cdk2.
@ast
Mice thrive without Cdk4 and Cdk2.
@en
Mice thrive without Cdk4 and Cdk2.
@nl
P2093
P2860
P1433
P1476
Mice thrive without Cdk4 and Cdk2.
@en
P2093
Alberto Martín
Antonio Cerqueira
Cédric Barrière
David Santamaría
Javier Galán
Mariano Barbacid
Pierre Dubus
Sagrario Ortega
P2860
P356
10.1016/J.MOLONC.2007.03.001
P577
2007-03-14T00:00:00Z